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Dendritic cell maturation by innate lymphocytes: 
coordinated stimulation of innate and adaptive immunity
 
Christian Münz, Ralph M. Steinman, and Shin-ichiro Fujii
 
Pathogen recognition by Toll-like receptors (TLRs) on dendritic cells (DCs) leads 
to DC maturation and the initiation of adaptive immunity. Recent studies have 
shown that innate lymphocytes—natural killer (NK), natural killer T (NKT), and 
 
  
 
 T cells—also trigger DC maturation. This interaction in turn expands and 
activates innate lymphocytes and initiates adaptive T cell immunity. Here, we 
comment on the evidence that these pathways are TLR independent and have 
the potential to respond to infection, malignancy, and immunotherapy.
 
DC maturation, first proposed as a crit-
ical step in immunogenicity 20 years
ago, is now accepted as a crucial com-
ponent of the induction of most adaptive
immune responses. The term maturation
refers to an intricate differentiation
process whereby DCs respond rapidly
to an environmental stimulus and be-
come capable of eliciting adaptive immu-
nity. The type of stimulus determines the
program of DC differentiation and the
subsequent host immune response. DCs
can directly sense pathogen compo-
nents via TLRs, and respond to this
recognition by up-regulating surface
costimulatory molecules, secreting cy-
tokines and chemokines, enhancing
antigen presentation, and migrating to
secondary lymphoid tissues (1). Some
features of DC maturation, such as the
up-regulation of CD86, can be in-
duced by proinflammatory cytokines,
but cytokines alone seem insufficient
for the induction of adaptive immunity
in vivo (2, 3). Additional changes can
be imparted to the DCs by CD40 li-
gation, which contributes to the gener-
ation of both CD4 and CD8 T cell im-
munity (2).
Innate immune cells also sense in-
fections and cellular transformation via
receptors other than TLRs. We will
first summarize recently identified mo-
lecular mechanisms used by NK cells,
NKT cells, and 
 
  
 
 T cells to detect
infected and transformed cells, then
release  cytokines such as interferon
(IFN)-
 
 
 
 and exert cytolytic activity.
These recognition mechanisms are now
being placed into the context of DC
biology. We will consider how innate
lymphocytes induce DC maturation,
which in turn expands the numbers
and function of both innate and adap-
tive lymphocytes. We propose that the
interaction of DCs with innate lym-
phocytes represents a major control
mechanism for immunity that is inde-
pendent of TLR ligands.
 
Detection of viruses and tumors 
by NK cells
 
NK cells, originally defined by their
ability to lyse tumor cells without prior
activation, recognize their targets via
activating and inhibitory receptors (4).
The balance of signals transmitted by
these receptors determines whether
NK cells are inhibited or activated.
Activating NK cell receptors include
Ly49H, the natural cytotoxicity recep-
tors (NCRs), and NKG2D (4). Ly49H
in mice and the NCRs NKp46 and
NKp44 in humans directly recognize
viral proteins on the surface of infected
cells. Ly49H detects the m157 protein
of murine cytomegalovirus (MCMV)
and is essential for the resistance to
MCMV infection in mice (4). The si-
alylated forms of NKp44 and NKp46
recognize hemaglutinins of para- and
orthomyxoviridae, such as influenza, on
the surface of infected cells (5). The
nature of NCR ligands on transformed
cells remains unclear, although heparan
sulfate proteoglycans have been im-
plicated in the NKp30- and NKp46-
mediated NK cell recognition of ade-
nocarcinoma cell lines (6). Furthermore,
it has been established that NCRs are
the main activating receptors for NK
cell recognition of melanoma and B
cell lymphomas (7).
Much more is known about the
tumor-associated ligands of NKG2D
(4). Both in humans and mice, NKG2D
recognizes self-molecules expressed on
the cell surface upon transformation or
infection. In humans, these include the
MHC class I chain-related proteins A
and B (MICA and MICB) and UL16
binding proteins (ULBP1-4) and, in
mice, the retinoic acid early inducible 1
protein family (Rae1
 
 
 
-
 
 
 
), H60, and mu-
rine ULBP-like transcript 1 (MULT1)
(4). These NKG2D ligands are found
on some melanomas, carcinomas, and
T cell lymphomas (7). In sum, activating
NK cell receptors can recognize virus-
infected or transformed cells by binding
to virus surface proteins or to up-reg-
ulated self-proteins that are ligands for
NKG2D.
NK cell activation is further en-
hanced by the absence of NK cell inhi-
bition. The inhibitory NK receptors of
the CD94/NKG2, Ly49, and killer cell
immunoglobulin-like receptor (KIR)
families recognize classical and nonclassi-
cal MHC class I molecules (4). Multiple
viral proteins, especially of the herpes-
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viridae family, down-regulate the ex-
pression of MHC class I molecules or
antigen processing (4). As a result of the
loss of MHC class I molecules, or “miss-
ing self,” inhibitory NK cell receptors
are not engaged, which results in en-
hanced NK cell activation and destruc-
tion of transformed and infected cells.
 
Detection of glycolipids on CD1d 
by NKT cells
 
Invariant NKT cells, which express both
NK cell markers and T cell receptors
(TCRs) that use a single V
 
 
 
 chain, rec-
ognize foreign and self-glycolipids pre-
sented by the nonclassical MHC class I
molecule CD1d (8). Natural CD1d
ligands are currently being identified.
One example is lipophosphoglycan from
 
Leishmania donovani
 
, a constituent of the
parasitic surface glycocalyx, which stim-
ulates IFN-
 
 
 
 secretion by a subset of he-
patic mouse NKT cells (9). Glycosyl-
ceramides from the gram-negative bacteria
 
Ehrlichia muris
 
 and certain 
 
Sphingomonas
 
species, and phosphatidylinositol manno-
side from mycobacterial membranes, are
also recognized by human and mouse
NKT cells (10–12). There is also evi-
dence that glycolipids, possibly glyco-
sylphosphatidylinositol from 
 
Plasmodium
 
and 
 
Trypanosoma
 
 parasites, are detected
by NKT cells (8). NKT cell stimulation
by other pathogens such as 
 
Salmonella
typhimurium
 
, 
 
Staphylococcus aureus
 
, and
 
Pseudomonas aeruginosa
 
 has also been re-
ported (8), but specific CD1d ligands
from these organisms have not been
identified. These findings suggest that
NKT cells are primarily involved in the
detection of bacterial and parasitic patho-
gens, whereas NK cell activity is focused
on recognition of viral infections.
Similar to NK cells, NKT cells are
able to detect altered self-ligands. The
ganglioside GD3, which is overex-
pressed on human melanoma cells, can
be cross-presented on CD1d to mouse
NKT cells (13). Most recently, the ly-
sosomal glycosphingolipid isoglobotri-
hexosylceramide was shown to be a
potent CD1d-restricted self-ligand that
stimulates mouse NKT cells (14). In fact,
a lack of isoglobotrihexosylceramide re-
sults in severe NKT cell deficiency. DCs
can be induced to present isoglobotri-
hexosylceramide upon TLR ligation by
gram-positive bacteria like 
 
Salmonella ty-
phimurium
 
 (10). Therefore, both self and
microbial glycolipids presented on CD1d
can elicit NKT cell activation.
 
Detection of microbial antigens 
and tumors by 
 
  
 
 T cells
 
  
 
 T cells, which express 
 
  
 
 TCRs in-
stead of the 
 
  
 
 TCRs found on classical
T cells, recognize microbial and tumor
antigens, typically small pyrophospho-
monoesters and alkylamines (15). Sim-
ilar to NK and NKT cells, 
 
  
 
 T cells
can also recognize microbial products
and self-molecules on infected or tumor
cells, including small organic molecules,
chaperone proteins, or nonclassical MHC
class I molecules. Pyrophosphomonoesters,
including isopentenyl pyrophosphate,
are natural antigens from Mycobacteria
such as 
 
M. tuberculosis
 
 (15) or accumulate
as mevalonate metabolites in tumor cells
such as breast carcinoma, facilitating rec-
ognition of tumors by invariant 
 
  
 
 T
cells (16). The same invariant 
 
  
 
 T cell
population detects bacterial alkylamines
(15) and aminobiphosphonates, which
are synthetic compounds used in cancer
therapy (17). Other 
 
  
 
 T cell popula-
tions recognize mycobacterial and tu-
mor-derived HSP60 molecules (15). In
addition, some murine 
 
  
 
 T cells seem
to directly recognize viral surface pro-
teins such as herpes simplex virus gly-
coprotein I (15). Finally, nonclassical
MHC class I molecules stimulate distinct
 
  
 
 T cells. MICA and MICB are recog-
nized by human intestinal 
 
  
 
 T cells
(18), and the MHC class Ib T10/T22
antigens bind to murine 
 
  
 
 T cell re-
ceptors (19). As is the case for NK cell
recognition, these nonclassical MHC
class I molecules are thought to be up-
regulated upon cell transformation and
infection. Moreover, in humans a sub-
population of peripheral blood 
 
  
 
 T
cells is also restricted by the non-
classical MHC class I molecule CD1c,
which presents microbial glycolipids
(15). In sum, 
 
  
 
 T cells recognize in-
fected and transformed cells via a di-
verse set of ligands that range from
small organic compounds to pathogen-
derived antigens and stress-induced
self-molecules.
 
Dendritic cell maturation by NK, NKT, 
and 
 
  
 
 T cells
 
DC maturation has been documented in
vitro and in vivo after NK cell recogni-
tion of MHC class I
 
low
 
 tumor cells (20),
NKT cell stimulation by the synthetic
invertebrate glycolipid 
 
 
 
-galactosylcer-
amide (
 
 
 
-GalCer) presented on DC
CD1d molecules (21, 22), and activation
of phosphoantigen-specific and CD1c-
restricted 
 
  
 
 T cell subsets (23, 24). After
activation, all three innate lymphocyte
populations were able to induce DC
maturation as evidenced by increased ex-
pression of CD86, IL-12 production,
and priming of T cell responses (2, 20,
22–25). TNF has been identified as a
crucial inducer of DC maturation in
these studies (2, 23–26). In addition,
CD40–CD40L interactions induced by
NKT cells allowed for priming of adap-
tive immune responses by DCs (2).
Thus, NK, NKT, and 
 
  
 
 T cells mature
DCs by a combination of cytokine- and
cell contact–dependent signals.
In turn, matured DCs also stimulate
NK, NKT, and 
 
  
 
 T cells for sustained
innate immune responses (21, 24, 26–
28). IL-12, IL-15, IL-2, and IFN
 
 
 
/
 
 
 
,
which are all produced by maturing
DCs, contribute to the activation of
different NK cell functions (29–31).
This interaction likely takes place at
sites of infection and in secondary lym-
phoid organs (27).
An important component of DC
maturation is the ability of the DC to
mediate lymphocyte differentiation.
The interaction of NK cells with DCs
in vivo assists in the T helper type 1
(Th1) cell polarization of primary im-
mune responses, most likely via secre-
tion of the Th1 cell–promoting cyto-
kine IFN-
 
 
 
 by the NK cells (32). The
interaction of NKT cells with antigen-
capturing DCs likewise allows for the
induction of antigen-specific, IFN-
 
 
 
–
producing CD4
 
 
 
 and CD8
 
 
 
 T cells
(2). Thus, when DCs are matured by
NK, NKT, and 
 
  
 
 T cells, the DCs
both augment innate responses and
prime adaptive immunity.
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Comparing DC maturation induced by 
TLRs or innate lymphocytes
 
DC maturation is a sensor that links in-
nate immune responses to adaptive
ones. During TLR-mediated DC matu-
ration, distinct TLR ligands likely evoke
distinct responses in DCs (1). This sig-
naling complexity is further increased by
the expression of distinct TLRs on dif-
ferent DC subsets, as well as by the dif-
ferences in adaptor molecules used by
different TLRs (1). One difference be-
tween TLR-induced versus innate lym-
phocyte-induced DC maturation is the
nature of the ligands. TLRs bind micro-
bial constituents (protein, DNA, and
RNA) or autoantigens that erroneously
mimic these pathogen components (33).
NK, NKT, and 
 
  
 
 T cells can also be
activated by self-molecules, but these
serve as desirable molecular beacons to
signal infection or transformation of
cells that display these molecules (4, 10,
15). This altered self-recognition by in-
nate lymphocytes allows DC maturation
in response to tumors or other stresses,
which may not express TLR ligands. In
addition, TLR ligands stimulate many
cell types, including epithelial cells, and
lead to systemic responses, whereas DC
maturation in response to innate lym-
phocytes is potentially a much more lo-
cal and very early event that is restricted
to the site of innate lymphocyte activa-
tion. In sum, NK, NKT, and 
 
  
 
 T cells
have considerable potential to induce
protective DC maturation after both lo-
cal expression of stress-induced mole-
cules and systemic spreading of patho-
gen-derived constituents.
Innate lymphocytes can also pro-
vide antigenic material for DCs. Frag-
ments of infected or tumor cells, gener-
ated during the destruction of target
cells by innate lymphocytes, are taken
up by DCs and displayed on MHC
molecules, thus eliciting an adaptive T
cell response in vivo (20) (Fig. 1).
 
DC activation by innate lymphocytes 
in immunotherapy
 
It should prove fruitful to harness in-
nate lymphocyte-mediated DC matu-
ration for immunotherapy, because the
innate lymphocytes themselves have
direct antitumor functions and they can
mobilize an adaptive immune response
via DCs. In other words, they act as
adjuvants. A recent study showed that
NKT cell activation induced by 
 
 
 
-Gal-
Cer–pulsed immature DCs also pro-
voked NK and T cell expansion in
patients with metastatic malignancies
(34). This study suggested that DCs ac-
tivated by one population of innate
lymphocytes, such as NKT cells, can
activate another group of innate lym-
phocytes, such as NK cells, to induce
antitumor effects. In another recent
study (28), mature 
 
 
 
-GalCer–pulsed
DCs induced a 
 
 
 
100-fold expansion of
NKT cells, which was sustained for up
to 6 months after vaccination. This
treatment also boosted memory T cell
responses against a persistent human
cytomegalovirus antigen, but not
against influenza antigens, except in
one patient, likely due to the reintro-
duction of influenza antigens from a re-
cent vaccination. These data suggest
that NKT cell–mediated immune acti-
vation can lead to enhanced T cell re-
sponses against antigens present in the
patient, possibly as a result of NKT
cell–mediated maturation of DCs that
can present antigenic peptides. Another
study showed that 
 
  
 
 T cells could be
stimulated with the aminobiphospho-
nate pamidronate plus low-dose IL-2
in relapsed non-Hodgkin lymphoma
and multiple myeloma patients (17). In
patients whose 
 
  
 
 T cells expanded in
response to pamidronate and IL-2 in
vitro, the treatment led to increased
numbers of 
 
  
 
 T cells in the peripheral
blood in 55% of patients and to clinical
improvement in 33% of the patients.
However, the induction of adaptive T
cell immunity was not analyzed in this
patient cohort. Finally, allogeneic he-
matopoetic stem cell transplantation
mediates a graft-versus-leukemia effect,
which has been ascribed to detection of
mismatched HLA molecules by NK
cells (35). This would suggest a major
role for suitably activated NK cells in
direct resistance to human leukemia.
The effect on adaptive antileukemia
immune responses has yet to be evalu-
ated. With these initial results on innate
lymphocyte activation in immunother-
apy, NK, NKT, and 
 
  
 
 T cell stimuli
should be considered in addition to
TLR stimuli as adjuvants for DC-based
vaccines as a way to enhance both in-
Figure 1. Innate lymphocytes mature DCs. Innate lymphocytes, including    T, NKT, and NK cells 
recognize pathogen-derived and self-antigens on infected cells, tumors, and stressed self-tissues 
(left). Their activation leads to DC maturation, presumably under conditions where the DCs are also 
presenting ligands recognized by innate lymphocytes. The DCs thus expand the innate response 
(bottom right) and also elicit adaptive immunity to processed antigens (top right), including those 
derived from cells lysed by innate lymphocytes. Cytokines and cell contact–dependent molecules 
mediate DC activation by different types of innate lymphocytes, whereas DCs produce cytokines that 
expand and differentiate additional innate and adaptive lymphocytes.
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nate and adaptive immune responses
against infectious diseases and tumors.
 
Conclusions
 
Molecular mechanisms are being identi-
fied to explain how innate NK, NKT,
and 
 
  
 
 T cells detect infected and trans-
formed cells, and directly provide resis-
tance at the level of cytolysis and cyto-
kine production. Another new area
relates to the consequences of innate
lymphocyte interactions with DCs. First,
the innate cells induce DC maturation
through cell contact mechanisms that re-
main to be unraveled. Second, the DCs
expand the number and enhance the
function of the innate lymphocytes. Fi-
nally, maturing DCs process antigens,
particularly from cells lysed by innate
lymphocytes, and elicit adaptive Th1-
type immunity. This newly recognized
cross talk between DCs and innate lym-
phocytes, which seems to occur largely
in the secondary lymphoid organs, is
starting to be exploited for therapeutic
purposes, because innate lymphocytes
serve as attractive adjuncts for tumor re-
sistance and also as adjuvants for initiat-
ing antigen-specific, cell-mediated im-
munity. Major goals for the future are to
identify mechanisms by which DCs ex-
pand and activate innate lymphocytes, to
understand the role of lymphoid organs
as sites where DCs and innate cells inter-
act to initiate adaptive immunity, and to
harness these pathways in therapy and
perhaps vaccination.
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